Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b dose escalation study of venetoclax in treatment-naive higher-risk myelodysplastic syndromes
2016-001657-41Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in myelodysplastic syndrome (MDS), sponsored by AbbVie Inc. Primary endpoints: Safety profile and Pharmacokinetics. Started Jan 2021; status: completed.
02
Drugs
venetoclax
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2016-001657-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001657-41.